Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Blood (2024) 143 (14): 1365–1378.

https://doi.org/10.1182/blood.2023023142

Published: 2024

Includes: Supplemental data

Journal Articles

Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo

Blood (2022) 140 (Supplement 1): 4493–4494.

https://doi.org/10.1182/blood-2022-165274

Published: 2022

Journal Articles

Studies of a mosaic patient with DBA and chimeric mice reveal erythroid cell–extrinsic contributions to erythropoiesis

Raymond T. Doty, Xing Fan, David J. Young, Jialiu Liang, Komudi Singh, Zahra Pakbaz, Ronan Desmond, Sara K. Young-Baird, Settara C. Chandrasekharappa, Frank X. Donovan, Susan R. Phelps, Thomas Winkler, Cynthia E. Dunbar, Janis L. Abkowitz

Blood (2022) 139 (23): 3439–3449.

https://doi.org/10.1182/blood.2021013507

Published: 2022

Includes: Supplemental data

Journal Articles

Prospective Phase I/II Study of Eltrombopag for the Treatment of Bone Marrow Failure in Fanconi Anemia

Ma Evette Barranta, Fariba Chinian, Katherine Roskom, Tarik Lott, Julie Erb-Alvarez, Katherine R. Calvo, Thomas Winkler, Neelam Giri, Andre Larochelle

Blood (2021) 138 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2021-148573

Published: 2021

Journal Articles

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

Marina Konopleva, Nitin Jain, Courtney L Andersen, Natalia Couto Francisco, Nairouz Elgeioushi, Rosalind Hobson, Martin Scott, John Stone, Shringi Sharma, Pablo Morentin Gutierrez, Raoul Tibes, Barry Davies, Thomas Winkler, Giulia Fabbri, Fathima Zumla Cader, Nicole McNeer

Blood (2021) 138 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2021-147482

Published: 2021

Journal Articles

A Diamond-Blackfan Anemia Patient's Response to Eltrombopag and Genomic Analysis in Different Lineages

Xing Fan, MD, David Young, MD, Thomas Winkler, MD, Zahra Pakbaz, MD, Stephanie Sellers, Ma Evette Barranta, Cynthia E. Dunbar, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138577

Published: 2020

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Blood (2020) 136 (Supplement 1): 49–51.

https://doi.org/10.1182/blood-2020-136922

Published: 2020

Journal Articles

Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron

David J Young, MDPhD, Xing Fan, MD, Emma Groarke, MD, Bhavisha A Patel, MD, Ronan Desmond, MD, Thomas Winkler, MD, Andre Larochelle, MD PhD, Katherine R. Calvo, MD PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141375

Published: 2020

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Thomas Winkler, Xing Fan, James Cooper, Ronan Desmond, David J. Young, Danielle M. Townsley, Phillip Scheinberg, Sophia Grasmeder, Andre Larochelle, Marie Desierto, Janet Valdez, Jennifer Lotter, Colin Wu, Ruba N. Shalhoub, Katherine R. Calvo, Neal S. Young, Cynthia E. Dunbar

Blood (2019) 133 (24): 2575–2585.

https://doi.org/10.1182/blood.2019000478

Published: 2019

Journal Articles

Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ

Luigi J. Alvarado, Heather D. Huntsman, Hai Cheng, Danielle M. Townsley, Thomas Winkler, Xingmin Feng, Cynthia E. Dunbar, Neal S. Young, Andre Larochelle

Blood (2019) 133 (19): 2043–2055.

https://doi.org/10.1182/blood-2018-11-884486

Published: 2019

Includes: Supplemental data

Journal Articles

Single Cell Transcriptome Analysis of GATA2 Deficiency in Hematopoiesis Modeled with Induced Pluripotent Stem Cells

Francis Guitart, BA, Moonjung Jung, MD, Stefan Cordes, MD PhD, Shiqin Yu, Jizhong Zou, So Gun Hong, PhD, Vinh Dang, Diego A Espinoza, BA, Amy Hsu, Steven M. Holland, MD, Danielle M. Townsley, MD MSc, Cynthia E. Dunbar, MD, Thomas Winkler, MD

Blood (2018) 132 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2018-99-118410

Published: 2018

Journal Articles

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Xing Fan, MD, Thomas Winkler, MD, Ronan Desmond, MD, Bogdan Dumitriu, MD, Danielle M. Townsley, MD MSc, Maria del Pilar Fernandez Ibanez, Fernanda Gutierrez-Rodrigues, PhD, Sophia Grasmeder, RN, Ma Evette Barranta, Diane Madey, Jennifer Lotter, Janet Valdez, Katherine R. Calvo, MD PhD, Colin Wu, PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2018) 132 (Supplement 1): 538.

https://doi.org/10.1182/blood-2018-99-112994

Published: 2018

Journal Articles

Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

Alana Vicente, MD, Fernanda Gutierrez-Rodrigues, PhD, Valentina Giudice, MD, Zhijie Wu, MD PhD, Sachiko Kajigaya, PhD, Maria del Pilar Fernandez Ibanez, Maher Albitar, MD, Barbara Weinstein, RN, Katherine R. Calvo, MD PhD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Cynthia E. Dunbar, MD, Neal S. Young, MD, Thomas Winkler, MD

Blood (2018) 132 (Supplement 1): 229.

https://doi.org/10.1182/blood-2018-99-119780

Published: 2018

Journal Articles

Eltrombopag mobilizes iron in patients with aplastic anemia

Zhen Zhao, Qian Sun, Lori J. Sokoll, Michael Streiff, Zhe Cheng, Sophie Grasmeder, Danielle M. Townsley, Neal S. Young, Cynthia E. Dunbar, Thomas Winkler

Blood (2018) 131 (21): 2399–2402.

https://doi.org/10.1182/blood-2018-01-826784

Published: 2018

Includes: Supplemental data

Journal Articles

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Thomas Winkler, MD, James N. Cooper, MD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Sophia Grasmeder, RN, Colin Wu, PhD, Jennifer Lotter, Marie J Desierto, MS, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Katherine R Calvo, MD PhD, Neal S. Young, MD, Cynthia E Dunbar, MD

Blood (2017) 130 (Supplement 1): 777.

https://doi.org/10.1182/blood.V130.Suppl_1.777.777

Published: 2017

NARROW

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo

Studies of a mosaic patient with DBA and chimeric mice reveal erythroid cell–extrinsic contributions to erythropoiesis

Prospective Phase I/II Study of Eltrombopag for the Treatment of Bone Marrow Failure in Fanconi Anemia

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

A Diamond-Blackfan Anemia Patient's Response to Eltrombopag and Genomic Analysis in Different Lineages

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ

Single Cell Transcriptome Analysis of GATA2 Deficiency in Hematopoiesis Modeled with Induced Pluripotent Stem Cells

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

Eltrombopag mobilizes iron in patients with aplastic anemia

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only